ROIV Stock Overview
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.90 |
| 52 Week High | US$13.24 |
| 52 Week Low | US$8.06 |
| Beta | 1.34 |
| 1 Month Change | 9.55% |
| 3 Month Change | 3.61% |
| 1 Year Change | 26.16% |
| 3 Year Change | 11.00% |
| 5 Year Change | n/a |
| Change since IPO | 4.81% |
Recent News & Updates
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21
Recent updates
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year
Aug 21Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M
Aug 15An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued
Aug 12Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Jun 30Shareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.4% | 1.0% | 1.2% |
| 1Y | 26.2% | 0.7% | 24.9% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: ROIV exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months.
Volatility Over Time: ROIV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 904 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn’s disease.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$8.82b |
| Earnings (TTM) | US$4.35b |
| Revenue (TTM) | US$123.24m |
2.0x
P/E Ratio71.3x
P/S RatioIs ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$123.24m |
| Cost of Revenue | US$538.30m |
| Gross Profit | -US$415.05m |
| Other Expenses | -US$4.77b |
| Earnings | US$4.35b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.40 |
| Gross Margin | -336.78% |
| Net Profit Margin | 3,531.18% |
| Debt/Equity Ratio | 6.8% |
How did ROIV perform over the long term?
See historical performance and comparison